Pure Global
NCT06345404

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis
Corvus Pharmaceuticals, Inc.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
Soquelitinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Corvus Pharmaceuticals, Inc.
Location
Burlingame, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2024
End date
Apr 01, 2025
Enrollment
64 participants
Primary outcome

Incidence of adverse events, changes in laboratory values, vital signs, and electrocardiograms

Summary

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate
 to severe AD

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06345404
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06345404 through Pure Global AI's free database. This Phase 1 trial is sponsored by Corvus Pharmaceuticals, Inc. and is currently Recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 64 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.